Search our team at AdventHealth Research Institute
-
NCT05611931
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
This study is not currently enrolling.Research Area: Cancer Research -
NCT05812807
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchTo evaluate whether observation results in a non-inferior RFS compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pCR after neoadjuvant chemotherapy with pembrolizumab
-
NCT0645646
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer ResearchResearch Location: Orlando, Florida -
NCT06456463
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Cancer Research -
NCT06285097
A Phase 1 Dose Escalation and Expansion Study To Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Antitumor Activity Of PF-07820435 as Monotherapy and In Combination in Participants With Advanced Solid Tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchStudy To Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, And Antitumor Activity Of PF-07820435 As Monotherapy And In Combination In Participants With Advanced Solid Tumors
-
NCT05904886
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)
This study is not currently enrolling.Associated Conditions: Liver CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this...
-
NCT06253130
EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
This study is not currently enrolling.Research Area: Cancer ResearchResearch Location: Celebration, FloridaThe study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in...
-
NCT04717414
ACE-536-MF-002: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)
This study is not currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe main purpose of this study is to see if people with MPN-associated myelofibrosis that need blood transfusions will stop needing RBC transfusions or require less frequent RBC transfusions by taking...
-
NCT05685004
Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltransferase negative (MGMT unmethylated) grade 4 astrocytoma (glioblastoma multiforme; glioblastoma; GBM).
This study is not currently enrolling.Associated Conditions: Brain CancerResearch Area: Cancer ResearchThis clinical trial is being performed because there is a need for safer and more effective treatments for glioblastomas. The purpose of this specific clinical study is to determine how safe and...
-
NCT05671510
PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
This study is not currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchThe main purpose of the study is to determine whether the study drug, ONC-392, is safe and well tolerated, and whether it is effective in treating lung cancer, in comparison with a standard of care...
-
NCT05840211
A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy ASCENT 07
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to see if sacituzumab govitecan can improve life spans of patients with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current...
-
NCT05514054
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThis study is being done to see how safe an investigational drug is and how well it will work to help people with Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative...